Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (101-110 of 147) with videos related to

Pageof 15
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
Antiviral Therapy|April 14, 2010
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patientsLucy Garvey, Ngaire Latch, Otto W Erlwein, et al.
Plos One|March 5, 2011
Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohortGabriel Kigen, Sylvester Kimaiyo, Winstone Nyandiko, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake CessationLaura Dickinson, H Manisha Yapa, Akil Jackson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2012
Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adultsMohammed Lamorde, Pauline Byakika-Kibwika, Marta Boffito, et al.
Open Forum Infectious Diseases|February 28, 2020
Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV TherapyBenjamin Schulte, Maximilian Wübbolding, Fiona Marra, et al.
The Journal of Antimicrobial Chemotherapy|February 14, 2014
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapyBorja Mora-Peris, Victoria Watson, Jaime H Vera, et al.
Journal of Viral Hepatitis|April 13, 2019
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysisDavid Back, Pamela Belperio, Mark Bondin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 10, 2023
Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the LiteratureDaryl Hodge, Eva Maria Hodel, Elen Hughes, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2010
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteersAkil Jackson, Andrew Hill, Rebekah Puls, et al.
Pageof 15

Showing results (101-110 of 147) with videos related to

Sort By:
Pageof 15
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
Antiviral Therapy|April 14, 2010
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patientsLucy Garvey, Ngaire Latch, Otto W Erlwein, et al.
Plos One|March 5, 2011
Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohortGabriel Kigen, Sylvester Kimaiyo, Winstone Nyandiko, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake CessationLaura Dickinson, H Manisha Yapa, Akil Jackson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2012
Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adultsMohammed Lamorde, Pauline Byakika-Kibwika, Marta Boffito, et al.
Open Forum Infectious Diseases|February 28, 2020
Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV TherapyBenjamin Schulte, Maximilian Wübbolding, Fiona Marra, et al.
The Journal of Antimicrobial Chemotherapy|February 14, 2014
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapyBorja Mora-Peris, Victoria Watson, Jaime H Vera, et al.
Journal of Viral Hepatitis|April 13, 2019
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysisDavid Back, Pamela Belperio, Mark Bondin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 10, 2023
Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the LiteratureDaryl Hodge, Eva Maria Hodel, Elen Hughes, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2010
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteersAkil Jackson, Andrew Hill, Rebekah Puls, et al.
Pageof 15